CNS Pharmaceuticals Company Presentation

CNS pharmaceuticals 18 Near Term Key Catalysts. • Orphan Drug Designation June 2020 • Submit IND for Berubicin 4Q 2020 • Initiate Phase 2 trial for Berubicin for GBM 1Q 2021 • Initiate WP1244 preclinical studies 4Q 2020 • WPD initiates clinical trials in Poland Adults: Phase 2 Q1 2021 Pediatrics: Phase 1 Q1 2021